179 related articles for article (PubMed ID: 12126319)
1. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia.
Marshall JK; Grootendorst PV; O'Brien BJ; Dolovich LR; Holbrook AM; Levy AR
CMAJ; 2002 Jun; 166(13):1655-62. PubMed ID: 12126319
[TBL] [Abstract][Full Text] [Related]
2. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs.
Grootendorst PV; Dolovich LR; O'Brien BJ; Holbrook AM; Levy AR
CMAJ; 2001 Oct; 165(8):1011-9. PubMed ID: 11699696
[TBL] [Abstract][Full Text] [Related]
3. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.
Grootendorst PV; Marshall JK; Holbrook AM; Dolovich LR; O'Brien BJ; Levy AR
Health Serv Res; 2005 Oct; 40(5 Pt 1):1297-317. PubMed ID: 16174135
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.
Schneeweiss S; Soumerai SB; Maclure M; Dormuth C; Walker AM; Glynn RJ
Clin Pharmacol Ther; 2003 Oct; 74(4):388-400. PubMed ID: 14534526
[TBL] [Abstract][Full Text] [Related]
5. Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing.
Barozzi N; Tett SE
Clin Ther; 2009 Apr; 31(4):849-61. PubMed ID: 19446158
[TBL] [Abstract][Full Text] [Related]
6. Effects of an evidence report and policies lifting reimbursement restrictions for acid suppressants: analysis of the Belgian national database.
van Driel ML; Vander Stichele R; Elseviers M; De Sutter A; De Maeseneer J; Christiaens T
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1113-22. PubMed ID: 18823069
[TBL] [Abstract][Full Text] [Related]
7. Health services utilization with reference drug pricing of histamine(2) receptor antagonists in British Columbia elderly.
Hazlet TK; Blough DK
Med Care; 2002 Aug; 40(8):640-9. PubMed ID: 12187178
[TBL] [Abstract][Full Text] [Related]
8. Cost analysis of a provincial drug program to guide the treatment of upper gastrointestinal disorders.
Bursey F; Crowley M; Janes C; Turner CJ
CMAJ; 2000 Mar; 162(6):817-23. PubMed ID: 10750472
[TBL] [Abstract][Full Text] [Related]
9. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
Johnson JT; Neill KK; Davis DA
J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
[TBL] [Abstract][Full Text] [Related]
10. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.
Schneeweiss S; Soumerai SB; Glynn RJ; Maclure M; Dormuth C; Walker AM
CMAJ; 2002 Mar; 166(6):737-45. PubMed ID: 11944760
[TBL] [Abstract][Full Text] [Related]
11. Differences in utilisation of gastroprotective drugs between 2001 and 2005 in Australia and Nova Scotia, Canada.
Tett SE; Sketris I; Cooke C; van Zanten SV; Barozzi N
Pharmacoepidemiol Drug Saf; 2013 Jul; 22(7):735-43. PubMed ID: 23559528
[TBL] [Abstract][Full Text] [Related]
12. A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia.
Grootendorst P; Stewart D
Health Econ; 2006 Jul; 15(7):735-42. PubMed ID: 16498702
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
Schneeweiss S; Walker AM; Glynn RJ; Maclure M; Dormuth C; Soumerai SB
N Engl J Med; 2002 Mar; 346(11):822-9. PubMed ID: 11893794
[TBL] [Abstract][Full Text] [Related]
14. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences.
Schneeweiss S; Maclure M; Dormuth CR; Glynn RJ; Canning C; Avorn J
Clin Pharmacol Ther; 2006 Apr; 79(4):379-88. PubMed ID: 16580906
[TBL] [Abstract][Full Text] [Related]
15. Medical evidence and health policy: a marriage of convenience? The case of proton pump inhibitors.
van Driel ML; Vander Stichele R; De Maeseneer J; De Sutter A; Christiaens T
J Eval Clin Pract; 2007 Aug; 13(4):674-80. PubMed ID: 17683313
[TBL] [Abstract][Full Text] [Related]
16. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
Lucas LM; Gerrity MS; Anderson T
Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299
[TBL] [Abstract][Full Text] [Related]
17. Reference-based pricing in British Columbia: implications for cardiologists--an analysis.
Boulet AP; Tessier G
Can J Cardiol; 1997 Jan; 13(1):46-51. PubMed ID: 9039064
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitors and hospital discharge rates for gastrointestinal events in Italy: a national ecological study.
Russo P; Brutti C
Clin Ther; 2007 Apr; 29(4):751-8. PubMed ID: 17617299
[TBL] [Abstract][Full Text] [Related]
19. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
Harris RA; Kuppermann M; Richter JE
Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
[TBL] [Abstract][Full Text] [Related]
20. Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents.
Schneeweiss S; Dormuth C; Grootendorst P; Soumerai SB; Maclure M
Med Care; 2004 Jul; 42(7):653-60. PubMed ID: 15213490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
